Last reviewed · How we verify
SAR442970
At a glance
| Generic name | SAR442970 |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis (PHASE2)
- A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease (PHASE2)
- Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa (PHASE2)
- A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SAR442970 CI brief — competitive landscape report
- SAR442970 updates RSS · CI watch RSS
- Sanofi portfolio CI